Literature DB >> 16261431

A novel apoptosis-inducing monoclonal antibody (anti-LHK) against a cell surface antigen on colon cancer cells.

Hidehiko Matsukawa1, Takanori Kanai, Makoto Naganuma, Nobuhiko Kamada, Tadakazu Hisamatsu, Hiromasa Takaishi, Haruhiko Ogata, Makio Mukai, Hiromasa Ishii, Tsuneyo Mimori, Mamoru Watanabe, Toshifumi Hibi.   

Abstract

BACKGROUND: Apoptosis is a crucial element in the behavior of mammalian cells in many different situations. We here report the establishment of a novel monoclonal antibody (anti-LHK mAb) that has apoptosis-inducing activity against colon cancer Colo205 cells.
METHODS: The mechanism of anti-LHK mAb-induced cell death was assessed by microscopic morphology, Annexin V/Hoechst 33528 staining, and detection of DNA fragmentation. The molecular weight of LHK antigen was determined by Western blotting. Growth inhibition of Colo205 cells induced by anti-LHK mAb was determined by in vitro and in vivo studies.
RESULTS: Anti-LHK reacted with a 70-kDa antigen and completely blocked the proliferation of Colo205 cells bearing LHK in vitro in a manner characteristic of apoptosis. Strikingly, anti-LHK mAb suppressed tumor growth in a murine peritoneal dissemination model.
CONCLUSIONS: LHK antigen, which is restricted to epithelial cells, may be a novel death receptor that plays a critical role in controlling the growth, invasion, and metastasis of human colon cancer cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16261431     DOI: 10.1007/s00535-005-1650-8

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  25 in total

1.  TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

Authors:  H Walczak; M A Degli-Esposti; R S Johnson; P J Smolak; J Y Waugh; N Boiani; M S Timour; M J Gerhart; K A Schooley; C A Smith; R G Goodwin; C T Rauch
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

2.  Monoclonal antibody-mediated tumor regression by induction of apoptosis.

Authors:  B C Trauth; C Klas; A M Peters; S Matzku; P Möller; W Falk; K M Debatin; P H Krammer
Journal:  Science       Date:  1989-07-21       Impact factor: 47.728

3.  Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes.

Authors:  K S Sellins; J J Cohen
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

Review 4.  Expression and function of death receptors and their natural ligands in the intestine.

Authors:  J Sträter; P Möller
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

5.  The receptor for the cytotoxic ligand TRAIL.

Authors:  G Pan; K O'Rourke; A M Chinnaiyan; R Gentz; R Ebner; J Ni; V M Dixit
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

6.  Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.

Authors:  R M Pitti; S A Marsters; S Ruppert; C J Donahue; A Moore; A Ashkenazi
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

7.  Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.

Authors:  A Oehm; I Behrmann; W Falk; M Pawlita; G Maier; C Klas; M Li-Weber; S Richards; J Dhein; B C Trauth
Journal:  J Biol Chem       Date:  1992-05-25       Impact factor: 5.157

8.  Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle.

Authors:  N Okada; T Mimori; R Mukai; H Kashiwagi; J A Hardin
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

9.  Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family.

Authors:  M A Degli-Esposti; P J Smolak; H Walczak; J Waugh; C P Huang; R F DuBose; R G Goodwin; C A Smith
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

10.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

Authors:  J O'Connell; G C O'Sullivan; J K Collins; F Shanahan
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

View more
  1 in total

Review 1.  Current status of monoclonal antibodies as therapeutic agents for solid cancer.

Authors:  Chiaki Okuse; Fumio Itoh
Journal:  J Gastroenterol       Date:  2005-10       Impact factor: 7.527

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.